Mandate

Vinge advises in Studentbostäder i Sverige AB’s issuance of sustainable bonds

Vinge advises in Studentbostäder i Sverige AB’s (the “Company”) issuance of a new senior unsecured sustainability bonds in an amount of SEK 500,000,000 within a framework amount of SEK 1,000,000,000 (the “Bonds”).

In connection with the transaction the Company established a sustainability bond framework in accordance with the 2018 ICMA Sustainability Bond Guidelines. The sustainability bond framework has been evaluated by an independent third party, ISS ESG, which assessed the framework and the related policy documents and reporting standards. The sustainability framework supports, among others, the UN’s global sustainable development goals; no. 7 “affordable and clean energy”, no. 11 “sustainable cities and communities” and no. 13 “climate action”.

In accordance with the terms and conditions, the Bonds are intended to be listed on the sustainable bond list of Nasdaq Stockholm. Nordea Bank Abp, Pareto Securities AB and Swedbank AB (publ) acted as joint bookrunners and arrangers in connection with the issuance of the Bonds.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda and Felix Möller (Banking and Finance) as well as Clara Sohlberg and David Bokliden (Capital Markets and Public M&A).

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025